price transparency
publication date
Payer
Trump's DOJ Accuses Medicare Advantage Insurers of Paying 'Kickbacks' for Primo Customers
DOJ alleges insurers labeled payments as 'marketing' or 'sponsorship' fees to get around rules that set caps on broker commissions.
Payer
Why Do Americans Pay More for Prescription Drugs?
Drug companies in the U.S. face few restraints on what to charge for their products. A bipartisan bill would penalize...
Revenue Cycle
Rev Cycle NOW Recap: Key Strategies for Improving Patient Engagement
Revenue cycle leaders from ProMedica and University Health Kansas City joined HealthLeaders for a candid talk on their strategies for...
Payer
Blockbuster Deal Will Wipe Out $30B in Medical Debt. Even Backers Say It's Not Enough.
Undue Medical Debt is retiring $30 billion worth of unpaid bills in a single transaction with Pendrick Capital Partners.
Revenue Cycle
HFMARCC 25: Improving the Patient Experience
Health systems can deliver more consumer-friendly features to improve the patient experience without breaking the bank.
Pharma
Top CA Dems Clash Over How to Rein In PBMs
As prescription drug prices continue to spiral and federal efforts to control them stall, state lawmakers are focusing on PBMs.
Revenue Cycle
With Trump on the Way, Advocates Look to States to Pick Up Medical Debt Fight
But new state initiatives may not be enough to protect Americans from medical debt.
Pharma
PBM Math: Big Chains Are Paid $23.55 To Fill a Blood Pressure Rx. Small Drugstores? $1.51.
Chains are paid well beyond family businesses for many of the same medications.
Revenue Cycle
WEDI Scrutinizes Price Estimates Citing Concerns Over Accuracy
In a letter the organization expresses concern over information unknown to the provider being used to estimate the cost of...
Payer
Contributed Content: 2 Alternatives to Ineffective Prescription Drug Rebates
Prescription drug rebates were once a good idea. Not any more.
Pharma
U.S. $772.5B Pharmacy Spend in 2023 Driven by Weight-Loss Drugs
Prescription drug spending grew by 13.5% in 2023, but drug cost inflation was lower than the CPI.